Cellectricon Q3 newsletter

Can’t see this email properly?

View Online
Intro image

Summertime and full speed ahead!


Welcome to our July newsletter. In this issue we are pleased to announce the addition of another highly respected specialist, Professor Henrik Zetterberg, to Cellectricon's scientific advisory board. Professor Zetterberg will be a key contributor in supporting our upcoming launch of a groundbreaking services offering targeting Alzheimer’s and other neurodegenerative disorders.


We are also providing a progress report from our ongoing collaboration with associate professor Camilla Svensson at Karolinska Institutet. Together we have been investigating whether in vivo changes in neuronal excitability induced by nerve injury or long-term inflammation are carried over to an in vitro setting. Data will be presented at the IASP World Congress on Pain in September and the full poster abstract is available below.

Photo Henrik Zetterberg

Professor Henrik Zetterberg brings neurodegenerative disease expertise to Cellectricon’s Scientific Advisory Board 


With a background in molecular biology and medicine, Professor Zetterberg has spent the past 10 years focusing on the development of biomarkers for Alzheimer’s disease and other brain disorders.


Learn More

Poster info image

Disease Relevance In Vitro? Comparison of Excitability in DRG Neurons from Neuropathic and Inflammatory Disease Models


Together with Camilla Svensson, Associate Professor at the Department of Physiology and Pharmacology, Karolinska Institutet, we will present data at the WCP meeting in Boston.


Poster info

Cellectricon Discovery Services

Functional and morphological screening in neurons


At Cellectricon we have a particular focus on diseases where neuronal excitability and synaptic function matters, such as chronic pain, epilepsy, Alzheimer’s disease and schizophrenia. With our discovery platform, we can create model systems for registering changes in neural activity, both at the cellular and network level.

The heart of our discovery platform is our proprietary Cellaxess® Elektra technology, a revolutionary automated platform for functional screening in living neurons. The system combines localized electric field manipulation with high speed fluorescence imaging to monitor parameters such as neuronal excitability, synaptic efficacy and synaptic plasticity in primary and stem cell-derived neurons. Cellaxess® Elektra is the only system enabling high quality phenotypic assays for compound characterization and target validation in a high-throughput format for these parameters


Learn more







IASP World Congress on Pain


Boston, US

Contact us to learn about poster presentation schedule and to arrange a meeting.



Cellectricon AB, Flöjelbergsgatan 8C, SE-431 37 Mölndal, Sweden, Org. No: 556602-0896
Phone: +46 (0)31 760 35 00    E-mail: info@cellectricon.com
This email has been sent to [email address suppressed] as a subscriber to Cellectricon AB.
If you no longer wish to receive these emails, please unsubscribe .